Who are Attendo's main competitors?

Named competitors: Ambea (AMBEA.ST), Humana (private) (private or unlisted), Vardaga (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Astrana Health (ASTH), NRC Health (NRC), Tokai (9729.T), Pro Medicus (PME.AX), Quest Diagnostics (DGX).

How has Attendo stock performed?

Over six months to 6 Nov 2026 the shares returned +22.5% against +36.4% for the median peer; over one year +62.7%.

← CockpitCompetitor Analysis › ATT.ST Attendo ABOpen in the cockpit ↗

Attendo ABATT.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Services to the Health Industry

Nordic provider of elderly and disability care services, operating care homes and home-care services mainly in Sweden and Nordics.

≈ A Nordic elderly/disability care operator like a smaller Genesis HealthcareMomentum leader 81

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.92B

US dollars, full cap

Free float

78%

of shares outstanding

$/day

$4.15M

20-day average traded

Fwd P/E

17.7×

forward earnings

ROIC−WACC

+1.5 pp

WACC 6.0%

Hurdle

-7 pp

Req g minus delivered

Close · SEKSEK 130.50

1D+16.2%

1W+11.8%

1M+8.5%

3M+22.3%

6M+22.5%

YTD+59.3%

1Y+62.7%

ATR %3.2%

52w lowhighat the 52-week high

What Attendo does

Nordic provider of elderly and disability care services, operating care homes and home-care services mainly in Sweden and Nordics.

In one line: A Nordic elderly/disability care operator like a smaller Genesis Healthcare.

Products and services

Elderly care homes
Home care services
Disability support services

Customers

Municipalities (payers)
Care recipients and families

Where it sits in the supply chain

Health Care
Care services
Elderly and disability residential/home…

What could go right

Aging Nordic population driving care demand
Municipal outsourcing of care services

What could go wrong

Public reimbursement rate/policy risk
Staffing shortages and wage inflation

Moat: narrow (regulatory licence, scale, installed base). Licensed care-provider status and scale in a publicly funded, contract-based Nordic welfare model, similar to peer Ambea.

Headquarters: Stockholm, Sweden · Founded: 1985 · Employees: 21,943

Named competitors

Ambea AMBEA.ST
Humana (private) private or unlisted
Vardaga (private) private or unlisted

Attendo at a glance

Size Attendo (ATT.ST) is a Sweden Health Care company (Services to the Health Industry) with a market value of $1.92B, the 88th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 130.50 on 6 Nov 2026.

Performance Over six months the shares gained 22.5%, against +36.4% for the median peer and +8.2% for the Sweden market (cap-weighted) — 3rd lowest of 6 in its peer set.

Growth Revenue fell 1.1% over the last twelve months (peer median +9.1%); the operating margin is 10.2% (peer median 11.1%).

Valuation It trades at 17.7× forward earnings against a peer median of 22.0× (2nd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.5 points above its cost of capital (6.0% WACC).

Relative performance

Six months, rebased to 100: Attendo against the median of its 5 peers (local-currency closes).

Attendo financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	SEK 19.0B	SEK 19.0B	SEK 19.0B	SEK 17.3B	SEK 14.5B
Revenue growth	—	0%	+10%	+19%	—
Gross profit	SEK 1.94B	SEK 3.20B	SEK 2.77B	SEK 2.38B	SEK 1.52B
EBITDA	SEK 4.00B	SEK 3.79B	SEK 3.39B	SEK 3.00B	SEK 2.05B
Net income	SEK 976M	SEK 813M	SEK 450M	SEK 376M	-SEK 45.0M
Free cash flow	SEK 2.73B	SEK 2.66B	SEK 2.27B	SEK 2.10B	SEK 1.17B
Capital expenditure	SEK 174M	SEK 200M	SEK 196M	SEK 149M	SEK 204M
Total debt	SEK 16.7B	SEK 16.4B	SEK 16.7B	SEK 14.7B	SEK 14.8B

Quarterly statements and history in the cockpit →

Attendo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Attendo is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Attendo is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Attendo is the large dot.

Attendo competitors and peer comparison

Head to head with its named competitors (ATT.ST vs AMBEA.ST)
Company	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g
Attendo ATT.ST	$1.92B	+23%	-1%	10%	17.7×	1.7%
Ambea AMBEA.ST	$1.63B	+30%	+13%	8%	15.8×	1.7%

How Attendo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Attendo against its 5 peers (data as of 6 Nov 2026)
Measure	ATT.ST	Peer median	Rank in peer set
1-month return	+8.5%	+10.8%	3rd lowest of 6
6-month return	+22.5%	+36.4%	3rd lowest of 6
Distance from 52-week high	0.0%	-9.9%	highest of 6
Revenue growth (TTM)	-1.1%	+9.1%	lowest of 6
Operating margin	10.2%	11.1%	3rd lowest of 6
Forward P/E	17.7×	22.0×	2nd cheapest of 6
Growth the price implies (Req g, 7 yrs)	1.7%	11.2%	2nd least demanding of 6
Growth delivered (Del g)	+9.1%	+6.2%	3rd highest of 6
Hurdle (Req g minus delivered)	-7.4 pp	+3.2 pp	3rd least demanding of 6
ROIC minus cost of capital	+1.5 pp	+5.4 pp	2nd lowest of 6
EV / EBITDA	8.5×	14.6×	2nd cheapest of 4
Net debt / EBITDA	3.8×	2.4×	2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Attendo ATT.ST	Sweden	$1.92B	+23%	-1%	10%	17.7×	1.7%	+9.1%
Astrana Health ASTH	United States	$1.71B	-12%	+59%	3%	19.3×	12.8%	+35.9%
NRC Health NRC	United States	$572M	+38%	+3%	11%	26.1×	11.2%	+0.6%
Tokai 9729.T	Japan	$553M	+3%	+5%	6%	12.4×	-13.2%	+6.2%
Pro Medicus PME.AX	Australia	$14.8B	+63%	+23%	75%	112.9×	55.0%	+31.0%
Quest Diagnostics DGX	United States	$28.1B	+36%	+9%	15%	22.0×	6.4%	+3.2%

Questions

Who are Attendo's main competitors?: Named competitors: Ambea (AMBEA.ST), Humana (private) (private or unlisted), Vardaga (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Astrana Health (ASTH), NRC Health (NRC), Tokai (9729.T), Pro Medicus (PME.AX), Quest Diagnostics (DGX).
Is Attendo expensive compared with its peers?: On forward p/e it trades at 17.7× against a peer median of 22.0×, 2nd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Attendo stock performed?: Over six months to 6 Nov 2026 the shares returned +22.5% against +36.4% for the median peer; over one year +62.7%.